NewAmsterdam Pharma Company Aktie
WKN DE: A3DUAC / ISIN: NL00150012L7
20.11.2024 15:52:26
|
NewAmsterdam Announces Positive Data From Phase 3 Trial Evaluating Obicetrapib+Ezetimibe
(RTTNews) - NewAmsterdam Pharma Co. N.V. (NAMS), Wednesday announced positive data from Phase 3 TANDEM clinical trial, evaluating the fixed-dose combination of 10 mg Obicetrapib and 10 mg Ezetimibe.
The trial involved adult patients with heterozygous familial hypercholesterolemia and/or atherosclerotic cardiovascular disease or multiple ASCVD risk factors, whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy.
The trial achieved all the co-primary points with the combination of Obicetrapib with Ezetimibe achieving an LS mean reduction of 48.6 percent compared to placebo at day 84.
The company expects the findings to support its regulatory filings globally.
Currently, NewAmsterdam's stock is falling 13.26 percent, to $20.15 on the Nasdaq.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu NewAmsterdam Pharma Company N.V. Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu NewAmsterdam Pharma Company N.V. Registered Shsmehr Analysen
Aktien in diesem Artikel
NewAmsterdam Pharma Company N.V. Registered Shs | 26,00 | 0,00% |
|